Product Description
Mechanisms of Action: Imaging Agent
Novel Mechanism: No
Modality: Diagnostic Agent
Route of Administration: Intravenous
FDA Designation: Fast Track - Priority Review - Brain Cancer *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Telix Pharm
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Austria, Netherlands, New Zealand
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Glioblastoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| IPAX-2 | P1 |
Recruiting |
Glioblastoma |
2025-06-01 |
27% |